|Day Low/High||212.51 / 225.18|
|52 Wk Low/High||212.49 / 343.96|
According to the charts, VEEV appears weak and prone to further declines ahead of earnings.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
On with September, the market's historically worst month
Plus, the latest monthly ISM Manufacturing survey sends a disturbing signal about prices and a quick option play thought about Veeva Systems.
Plus, checking the post-earnings reactions of Salesforce.com, Costco, Ulta Beauty and Veeva Systems.
The banks are parking large amounts of dough at the Fed every night. Last Friday's number was the highest single day total since 2017.
Everything came up roses Monday -- except for what matters most, broad participation.
If you're a trader, you either lock on a core of stocks and trade only those, or you create fluid watchlists.
The CRM software giant sports relatively low sales and billings multiples, and it stands to benefit in several ways from COVID's impact on enterprise tech adoption.
Our latest analysis and trading strategy for the cloud healthcare software provider.
Apple has placed highs at ever dwindling prices and lows at ever increasing prices. Withering formations like this often foretell explosive moves one way or the other.
Equity markets have run wild since Oct. 30, and it is the more economically sensitive indices that have really taken flight.
What the Nasdaq experienced Monday is known not just as an 'Outside Day,' but an 'Outside Reversal,' and these can be dangerous.
Covid itself, and therapeutics or vaccines associated with taking on the SARS-CoV-2 coronavirus, is under a public microscope.
Now, that we have confirmation from the Nasdaq Composite, I think we can say equity markets are indeed back in what I would consider an uptrend.
Plus, quick looks at the presidential line of succession and at ongoing foot-dragging in Congress.
RedHill Biopharma has adopted 'Veeva Vault CDMS', Veeva's modern cloud platform.
Plus, Veeva Systems reports stellar results and ups its guidance.
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
The trend still believes in Congress for whatever reason, and perhaps most importantly, in an effective vaccine and effective Covid treatments versus Covid sooner rather than the later.
It might be a good time to buy the stock because of its recent pullback, but there also is an ETF traders might consider if the telemedicine sector is of interest.
I would wait until the next down day, and there will be one.
Are equity markets still in a confirmed uptrend? It depends on which index you look at.
I'll be taking at least a third of my long off ahead of the numbers this afternoon.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
In months ahead stock should rise, with price targets of $200, $215 and $235.
The technical signals for the technology provider to the life science industry show its shares have upside potential.